Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-DFO-GmAb PET/CT vs Contrast-Enhanced CT for Detection of Recurrent Clear Cell Renal Cell Carcinoma After Surgery
NCT06447103Phase 2Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Aug 2024
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 89Zr-DFO-girentuximab in clear cell renal cell carcinoma (ccRCC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Aug 2024; status: recruiting.
02
Drugs
89Zr-DFO-girentuximab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06447103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06447103.